STOCK TITAN

[Form 4] Amphastar Pharmaceuticals, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Negative)
Form Type
4

Floyd F. Petersen, a director of Amphastar Pharmaceuticals, Inc. (AMPH), sold 500 shares of the company's common stock on 10/01/2025 at a weighted-average price of $27.2048 per share. The sale was made under a pre-established Rule 10b5-1 trading plan adopted on 11/26/2024. After the reported sale, Mr. Petersen beneficially owned 76,031 shares, held directly. The Form 4 was signed on behalf of the reporting person by Eva Wen as power of attorney on 10/02/2025. The registrant will provide, upon request, details on the number of shares sold at each execution price within the reported range of $26.74 to $27.39.

Floyd F. Petersen, direttore di Amphastar Pharmaceuticals, Inc. (AMPH), ha venduto 500 azioni ordinarie della società il 10/01/2025 ad un prezzo medio ponderato di $27,2048 per azione. La vendita è stata effettuata ai sensi di un predefinito piano di trading Rule 10b5-1 adottato il 26/11/2024. Dopo la vendita segnalata, il signor Petersen deteneva beneficiariamente 76.031 azioni, detenute direttamente. Il modulo 4 è stato firmato a nome della persona indicata dal rappresentante legale in data 02/10/2025. Il registrante fornirà, su richiesta, dettagli sul numero di azioni vendute a ciascun prezzo di esecuzione all'interno dell'intervallo riportato di $26,74 a $27,39.

Floyd F. Petersen, un director de Amphastar Pharmaceuticals, Inc. (AMPH), vendió 500 acciones comunes de la empresa el 01/10/2025 a un precio medio ponderado de $27.2048 por acción. La venta se realizó bajo un plan de negociación Rule 10b5-1 preestablecido adoptado el 26/11/2024. Después de la venta reportada, el Sr. Petersen poseía beneficiosamente 76,031 acciones, mantenidas directamente. El Formulario 4 fue firmado en nombre de la persona informante por Eva Wen como poder notarial el 02/10/2025. El registrante proporcionará, a solicitud, detalles sobre el número de acciones vendidas a cada precio de ejecución dentro del rango informado de $26.74 a $27.39.

Floyd F. Petersen, Amphastar Pharmaceuticals, Inc. (AMPH)의 이사로서 500주를 2025년 10월 1일에 시가가 가중평균 $27.2048달러 per 주로 매각했습니다. 매각은 사전 수립된 Rule 10b5-1 거래 계획에 따라 이루어졌으며, 2024년 11월 26일에 채택되었습니다. 보고된 매각 후 Petersen 씨는 76,031주를 직접 보유하고 있습니다. 양도양도인(공문)으로 서명된 Form 4는 보고자 대리인 Eva Wen의 권한 위임에 의해 2025년 10월 2일에 서명되었습니다. 등록자는 요청 시 보고된 범위 $26.74에서 $27.39 사이의 각 실행 가격으로 매도된 주식 수에 대한 세부 정보를 제공합니다.

Floyd F. Petersen, directeur de Amphastar Pharmaceuticals, Inc. (AMPH), a vendu 500 actions ordinaires de l'entreprise le 01/10/2025 à un cours moyen pondéré de $27.2048 par action. La vente a été réalisée dans le cadre d'un plan de négociation Rule 10b5-1 préétabli adopté le 26/11/2024. Après la vente signalée, M. Petersen détenait bénéfficiairement 76 031 actions, détenues directement. Le Formulaire 4 a été signé au nom de la personne signalée par procuration par Eva Wen le 02/10/2025. L'émetteur fournira, sur demande, des détails sur le nombre d'actions vendues à chaque prix d'exécution dans la plage indiquée de $26.74 à $27.39.

Floyd F. Petersen, Direktor von Amphastar Pharmaceuticals, Inc. (AMPH), verkaufte 500 Stammaktien des Unternehmens am 01.10.2025 zu einem gewichteten Durchschnittspreis von $27.2048 pro Aktie. Der Verkauf erfolgte im Rahmen eines vorab festgelegten Rule 10b5-1 Handelsplans, der am 26.11.2024 angenommen wurde. Nach dem gemeldeten Verkauf besaß Herr Petersen vorteilhaft 76.031 Aktien, direkt gehalten. Das Form 4 wurde im Namen der meldenden Person von Eva Wen als Bevollmächtigte/r am 02.10.2025 unterschrieben. Die Emittentin wird auf Anfrage Details zur Anzahl der Aktien, die zu jedem Ausführungspreis innerhalb des gemeldeten Bereichs von $26.74 bis $27.39 verkauft wurden, bereitstellen.

فلويد ف. بيترسن، مدير في Amphastar Pharmaceuticals, Inc. (AMPH)، باع 500 سهماً عادياً من أسهم الشركة في 01/10/2025 بسعرٍ مُوزَّع بالوزن قدره $27.2048 للسهم. تمت الصفقة بموجب خطة تداول Rule 10b5-1 مُسبقة الإعداد اعتمدت في 26/11/2024. بعد البيع المبلغ عنه، كان السيد بيترسن يملك فائدة ملكية قدرها 76,031 سهماً، مملوكة مباشرة. تم توقيع النموذج Form 4 نيابة عن الشخص المبلغ عنه بواسطة Eva Wen باعتبارها توكيلًا بتاريخ 02/10/2025. سيقدم المُسجِّل، عند الطلب، تفاصيل عن عدد الأسهم المباعة عند كل سعر تنفيذ ضمن النطاق المذكور من $26.74 إلى $27.39.

Floyd F. Petersen, Amphastar Pharmaceuticals, Inc.(AMPH)的 董事,在 2025/01/10 以加权平均价格 $27.2048 每股出售了 500 股公司的普通股。此次出售是在于 Rule 10b5-1 交易计划 预先设定的框架下于 2024/11/26 通过。报告的出售后,Petersen 先生实际持有 76,031 股,直接持有。 Form 4 由报告人授权代理人 Eva Wen 代表于 2025/10/02 签署。发行人将应要求提供在报道区间 $26.74$27.39 内每个执行价格的成交股数明细。

Positive
  • Sale effected under a Rule 10b5-1 plan adopted on 11/26/2024
Negative
  • None.

Floyd F. Petersen, direttore di Amphastar Pharmaceuticals, Inc. (AMPH), ha venduto 500 azioni ordinarie della società il 10/01/2025 ad un prezzo medio ponderato di $27,2048 per azione. La vendita è stata effettuata ai sensi di un predefinito piano di trading Rule 10b5-1 adottato il 26/11/2024. Dopo la vendita segnalata, il signor Petersen deteneva beneficiariamente 76.031 azioni, detenute direttamente. Il modulo 4 è stato firmato a nome della persona indicata dal rappresentante legale in data 02/10/2025. Il registrante fornirà, su richiesta, dettagli sul numero di azioni vendute a ciascun prezzo di esecuzione all'interno dell'intervallo riportato di $26,74 a $27,39.

Floyd F. Petersen, un director de Amphastar Pharmaceuticals, Inc. (AMPH), vendió 500 acciones comunes de la empresa el 01/10/2025 a un precio medio ponderado de $27.2048 por acción. La venta se realizó bajo un plan de negociación Rule 10b5-1 preestablecido adoptado el 26/11/2024. Después de la venta reportada, el Sr. Petersen poseía beneficiosamente 76,031 acciones, mantenidas directamente. El Formulario 4 fue firmado en nombre de la persona informante por Eva Wen como poder notarial el 02/10/2025. El registrante proporcionará, a solicitud, detalles sobre el número de acciones vendidas a cada precio de ejecución dentro del rango informado de $26.74 a $27.39.

Floyd F. Petersen, Amphastar Pharmaceuticals, Inc. (AMPH)의 이사로서 500주를 2025년 10월 1일에 시가가 가중평균 $27.2048달러 per 주로 매각했습니다. 매각은 사전 수립된 Rule 10b5-1 거래 계획에 따라 이루어졌으며, 2024년 11월 26일에 채택되었습니다. 보고된 매각 후 Petersen 씨는 76,031주를 직접 보유하고 있습니다. 양도양도인(공문)으로 서명된 Form 4는 보고자 대리인 Eva Wen의 권한 위임에 의해 2025년 10월 2일에 서명되었습니다. 등록자는 요청 시 보고된 범위 $26.74에서 $27.39 사이의 각 실행 가격으로 매도된 주식 수에 대한 세부 정보를 제공합니다.

Floyd F. Petersen, directeur de Amphastar Pharmaceuticals, Inc. (AMPH), a vendu 500 actions ordinaires de l'entreprise le 01/10/2025 à un cours moyen pondéré de $27.2048 par action. La vente a été réalisée dans le cadre d'un plan de négociation Rule 10b5-1 préétabli adopté le 26/11/2024. Après la vente signalée, M. Petersen détenait bénéfficiairement 76 031 actions, détenues directement. Le Formulaire 4 a été signé au nom de la personne signalée par procuration par Eva Wen le 02/10/2025. L'émetteur fournira, sur demande, des détails sur le nombre d'actions vendues à chaque prix d'exécution dans la plage indiquée de $26.74 à $27.39.

Floyd F. Petersen, Direktor von Amphastar Pharmaceuticals, Inc. (AMPH), verkaufte 500 Stammaktien des Unternehmens am 01.10.2025 zu einem gewichteten Durchschnittspreis von $27.2048 pro Aktie. Der Verkauf erfolgte im Rahmen eines vorab festgelegten Rule 10b5-1 Handelsplans, der am 26.11.2024 angenommen wurde. Nach dem gemeldeten Verkauf besaß Herr Petersen vorteilhaft 76.031 Aktien, direkt gehalten. Das Form 4 wurde im Namen der meldenden Person von Eva Wen als Bevollmächtigte/r am 02.10.2025 unterschrieben. Die Emittentin wird auf Anfrage Details zur Anzahl der Aktien, die zu jedem Ausführungspreis innerhalb des gemeldeten Bereichs von $26.74 bis $27.39 verkauft wurden, bereitstellen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Petersen Floyd F.

(Last) (First) (Middle)
C/O AMPHASTAR PHARMACEUTICALS, INC.
11570 6TH STREET

(Street)
RANCHO CUCAMONGA CA 91730

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Amphastar Pharmaceuticals, Inc. [ AMPH ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/01/2025 S(1) 500 D $27.2048(2) 76,031 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2024.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.74 to $27.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
/s/ Eva Wen, by power of attorney 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Amphastar director Floyd F. Petersen sell (AMPH)?

The director sold 500 shares of Amphastar common stock on 10/01/2025.

At what price were the AMPH shares sold?

The shares were sold at a weighted-average price of $27.2048, in transactions ranging from $26.74 to $27.39.

Was the sale part of a trading plan for AMPH insiders?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 11/26/2024.

How many AMPH shares does Petersen own after the sale?

Following the sale, Mr. Petersen beneficially owned 76,031 shares, held directly.

Who signed the Form 4 for Petersen?

The Form 4 was signed by Eva Wen by power of attorney on 10/02/2025.
Amphastar Pharma

NASDAQ:AMPH

AMPH Rankings

AMPH Latest News

AMPH Latest SEC Filings

AMPH Stock Data

1.20B
35.33M
24.02%
71.85%
8.94%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
RANCHO CUCAMONGA